Inspire Medical Unveils Next-Gen Neurostimulator Amid 31.5% Stock Dip
By ATTN Desk · Editorial oversight: Sean Han
Company Overview
Inspire Medical Systems Inc (NYS: INSP) is a Golden Valley, Minnesota–based medical technology company founded in 2007 as a spin-out from Medtronic. Its flagship Inspire® system is the first and only FDA-approved fully implanted neurostimulation device for moderate to severe obstructive sleep apnea (OSA). The system comprises an implant, a handheld remote, and a mobile app for patient control and clinician data sharing.
Corporate Structure and Workforce
As of August 2025, Inspire employs between 1,001 and 5,000 professionals across clinical, manufacturing, and corporate functions. The company provides a suite of employee benefits, including medical and vision coverage, a 15% discounted employee stock purchase plan, Roth and pretax 401(k) options, tuition reimbursement, and access to professional development resources such as LinkedIn Learning. Inspire maintains a nationwide network of Inspire-trained providers.
Neurostimulation by Milad Fakurian
Recent Developments and News
In July 2025, Inspire updated its website to feature the next-generation Inspire® implant, highlighting enhanced patient comfort and a streamlined procedure. On August 19, 2025, and September 12, 2025, Inspire patient ambassadors will participate in Minnesota Twins games at Target Field to discuss therapy experiences with attendees. Since 2021, the company has partnered with the American Academy of Sleep Medicine Foundation to host annual forums for sleep medicine fellows, most recently involving 125 fellows in Minneapolis for hands-on training in hypoglossal nerve stimulation.
Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (2025-08-05) | $89.02 |
| Price Change (%) | −31.50% |
| Trading Volume (shares) | 108,353 |
On August 5, 2025, INSP shares closed at $89.02, which represents a 31.5% decline from the 52-week high. The average daily trading volume stood at 108,353 shares. Strategically, Inspire focuses on expanding its patient and provider network while advancing its neurostimulation platform through iterative product enhancements and promoting clinical adoption through training partnerships.
Market Position and Industry Context
OSA affects millions of patients globally, many of whom do not adhere to continuous positive airway pressure (CPAP) therapy. Inspire occupies a specialized market segment by offering a mask-free, implanted alternative tailored for patients who are intolerant to CPAP therapy. The global OSA treatment market in 2025 is influenced by rising disease prevalence, advancements in neurostimulation technologies, and increasing clinical validation of implantable treatment solutions.
tl;dr
On August 5, 2025, Inspire Medical Systems shares closed at $89.02 (−31.5% from its 52-week high) with 108,353 shares traded. In July 2025, the company introduced its next-generation Inspire® implant featuring a streamlined procedure. Patient ambassadors will be present at Minnesota Twins games on August 19 and September 12, 2025. Continuing partnership with the AASM Foundation supports provider training initiatives. Future growth is reliant on broader clinical adoption and entry into the CPAP-intolerant patient segment.